PEDIATRIX MEDICAL GROUP INC (MD) Fundamental Analysis & Valuation
NYSE:MD • US58502B1061
Current stock price
23.07 USD
+0.86 (+3.87%)
At close:
22.9798 USD
-0.09 (-0.39%)
After Hours:
This MD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. MD Profitability Analysis
1.1 Basic Checks
- In the past year MD was profitable.
- MD had a positive operating cash flow in the past year.
- The reported net income has been mixed in the past 5 years: MD reported negative net income in multiple years.
- Each year in the past 5 years MD had a positive operating cash flow.
1.2 Ratios
- With an excellent Return On Assets value of 7.36%, MD belongs to the best of the industry, outperforming 88.00% of the companies in the same industry.
- MD has a Return On Equity of 19.10%. This is amongst the best in the industry. MD outperforms 86.00% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 9.88%, MD belongs to the top of the industry, outperforming 82.00% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for MD is in line with the industry average of 8.51%.
- The last Return On Invested Capital (9.88%) for MD is above the 3 year average (8.21%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.36% | ||
| ROE | 19.1% | ||
| ROIC | 9.88% |
ROA(3y)0.01%
ROA(5y)1.53%
ROE(3y)-0.32%
ROE(5y)4.22%
ROIC(3y)8.21%
ROIC(5y)7.97%
1.3 Margins
- Looking at the Profit Margin, with a value of 8.64%, MD belongs to the top of the industry, outperforming 92.00% of the companies in the same industry.
- In the last couple of years the Profit Margin of MD has grown nicely.
- The Operating Margin of MD (12.07%) is better than 85.00% of its industry peers.
- MD's Operating Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.07% | ||
| PM (TTM) | 8.64% | ||
| GM | N/A |
OM growth 3Y5.99%
OM growth 5Y4.02%
PM growth 3Y36.96%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. MD Health Analysis
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so MD is still creating some value.
- MD has less shares outstanding than it did 1 year ago.
- MD has less shares outstanding than it did 5 years ago.
- MD has a better debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 2.13 indicates that MD is not a great score, but indicates only limited risk for bankruptcy at the moment.
- MD has a Altman-Z score (2.13) which is comparable to the rest of the industry.
- MD has a debt to FCF ratio of 2.36. This is a good value and a sign of high solvency as MD would need 2.36 years to pay back of all of its debts.
- Looking at the Debt to FCF ratio, with a value of 2.36, MD is in the better half of the industry, outperforming 72.00% of the companies in the same industry.
- A Debt/Equity ratio of 0.66 indicates that MD is somewhat dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.66, MD is in line with its industry, outperforming 53.00% of the companies in the same industry.
- Although MD's pure debt/equity ratio does not look good, it has limited outstanding debt compared to the Free Cash Flow. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | 2.36 | ||
| Altman-Z | 2.13 |
ROIC/WACC1.15
WACC8.61%
2.3 Liquidity
- A Current Ratio of 1.66 indicates that MD should not have too much problems paying its short term obligations.
- MD's Current ratio of 1.66 is fine compared to the rest of the industry. MD outperforms 67.00% of its industry peers.
- MD has a Quick Ratio of 1.66. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
- MD's Quick ratio of 1.66 is fine compared to the rest of the industry. MD outperforms 68.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.66 | ||
| Quick Ratio | 1.66 |
3. MD Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 36.24% over the past year.
- The Earnings Per Share has been growing by 10.01% on average over the past years. This is quite good.
- Looking at the last year, MD shows a decrease in Revenue. The Revenue has decreased by -4.92% in the last year.
- Measured over the past years, MD shows a small growth in Revenue. The Revenue has been growing by 1.99% on average per year.
EPS 1Y (TTM)36.24%
EPS 3Y6.72%
EPS 5Y10.01%
EPS Q2Q%-1.96%
Revenue 1Y (TTM)-4.92%
Revenue growth 3Y-0.99%
Revenue growth 5Y1.99%
Sales Q2Q%-1.71%
3.2 Future
- The Earnings Per Share is expected to grow by 0.99% on average over the next years.
- MD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.93% yearly.
EPS Next Y13.36%
EPS Next 2Y8.67%
EPS Next 3Y4.87%
EPS Next 5Y0.99%
Revenue Next Year1.07%
Revenue Next 2Y1.84%
Revenue Next 3Y2.77%
Revenue Next 5Y3.93%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. MD Valuation Analysis
4.1 Price/Earnings Ratio
- MD is valuated reasonably with a Price/Earnings ratio of 11.36.
- Based on the Price/Earnings ratio, MD is valued cheaply inside the industry as 91.00% of the companies are valued more expensively.
- When comparing the Price/Earnings ratio of MD to the average of the S&P500 Index (27.89), we can say MD is valued rather cheaply.
- Based on the Price/Forward Earnings ratio of 10.03, the valuation of MD can be described as reasonable.
- Based on the Price/Forward Earnings ratio, MD is valued cheaply inside the industry as 91.00% of the companies are valued more expensively.
- The average S&P500 Price/Forward Earnings ratio is at 38.50. MD is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.36 | ||
| Fwd PE | 10.03 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, MD is valued cheaper than 84.00% of the companies in the same industry.
- MD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MD is cheaper than 88.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.59 | ||
| EV/EBITDA | 7.47 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- MD has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)0.85
PEG (5Y)1.14
EPS Next 2Y8.67%
EPS Next 3Y4.87%
5. MD Dividend Analysis
5.1 Amount
- No dividends for MD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
MD Fundamentals: All Metrics, Ratios and Statistics
23.07
+0.86 (+3.87%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-19 2026-02-19/bmo
Earnings (Next)04-30 2026-04-30/bmo
Inst Owners103.94%
Inst Owner Change-0.01%
Ins Owners2.05%
Ins Owner Change-0.8%
Market Cap1.92B
Revenue(TTM)1.91B
Net Income(TTM)165.39M
Analysts78.67
Price Target21.76 (-5.68%)
Short Float %4.34%
Short Ratio3.92
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.87%
Min EPS beat(2)-9.94%
Max EPS beat(2)39.68%
EPS beat(4)3
Avg EPS beat(4)20.9%
Min EPS beat(4)-9.94%
Max EPS beat(4)39.68%
EPS beat(8)7
Avg EPS beat(8)17.99%
EPS beat(12)7
Avg EPS beat(12)8.59%
EPS beat(16)8
Avg EPS beat(16)5.12%
Revenue beat(2)1
Avg Revenue beat(2)-0.49%
Min Revenue beat(2)-1.41%
Max Revenue beat(2)0.42%
Revenue beat(4)1
Avg Revenue beat(4)-1.1%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)0.42%
Revenue beat(8)2
Avg Revenue beat(8)-1.43%
Revenue beat(12)2
Avg Revenue beat(12)-2.28%
Revenue beat(16)2
Avg Revenue beat(16)-2.52%
PT rev (1m)-0.78%
PT rev (3m)-5.88%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.3%
EPS NY rev (1m)0%
EPS NY rev (3m)2.14%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.72%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.59%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.36 | ||
| Fwd PE | 10.03 | ||
| P/S | 1 | ||
| P/FCF | 7.59 | ||
| P/OCF | 7.07 | ||
| P/B | 2.21 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.47 |
EPS(TTM)2.03
EY8.8%
EPS(NY)2.3
Fwd EY9.97%
FCF(TTM)3.04
FCFY13.18%
OCF(TTM)3.26
OCFY14.15%
SpS23.04
BVpS10.42
TBVpS-4.96
PEG (NY)0.85
PEG (5Y)1.14
Graham Number21.8192 (-5.42%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.36% | ||
| ROE | 19.1% | ||
| ROCE | 12.93% | ||
| ROIC | 9.88% | ||
| ROICexc | 13.71% | ||
| ROICexgc | 1686.9% | ||
| OM | 12.07% | ||
| PM (TTM) | 8.64% | ||
| GM | N/A | ||
| FCFM | 13.2% |
ROA(3y)0.01%
ROA(5y)1.53%
ROE(3y)-0.32%
ROE(5y)4.22%
ROIC(3y)8.21%
ROIC(5y)7.97%
ROICexc(3y)10.42%
ROICexc(5y)9.77%
ROICexgc(3y)618.91%
ROICexgc(5y)394.62%
ROCE(3y)10.75%
ROCE(5y)10.43%
ROICexgc growth 3Y208.98%
ROICexgc growth 5Y85.34%
ROICexc growth 3Y17.7%
ROICexc growth 5Y11.82%
OM growth 3Y5.99%
OM growth 5Y4.02%
PM growth 3Y36.96%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.85
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | 2.36 | ||
| Debt/EBITDA | 2.26 | ||
| Cap/Depr | 84.57% | ||
| Cap/Sales | 0.96% | ||
| Interest Coverage | 6.72 | ||
| Cash Conversion | 107.19% | ||
| Profit Quality | 152.75% | ||
| Current Ratio | 1.66 | ||
| Quick Ratio | 1.66 | ||
| Altman-Z | 2.13 |
F-Score8
WACC8.61%
ROIC/WACC1.15
Cap/Depr(3y)81.68%
Cap/Depr(5y)85.74%
Cap/Sales(3y)1.24%
Cap/Sales(5y)1.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.24%
EPS 3Y6.72%
EPS 5Y10.01%
EPS Q2Q%-1.96%
EPS Next Y13.36%
EPS Next 2Y8.67%
EPS Next 3Y4.87%
EPS Next 5Y0.99%
Revenue 1Y (TTM)-4.92%
Revenue growth 3Y-0.99%
Revenue growth 5Y1.99%
Sales Q2Q%-1.71%
Revenue Next Year1.07%
Revenue Next 2Y1.84%
Revenue Next 3Y2.77%
Revenue Next 5Y3.93%
EBIT growth 1Y25.81%
EBIT growth 3Y4.93%
EBIT growth 5Y6.1%
EBIT Next Year16.33%
EBIT Next 3Y6.84%
EBIT Next 5YN/A
FCF growth 1Y36.89%
FCF growth 3Y22.56%
FCF growth 5Y7.52%
OCF growth 1Y31.23%
OCF growth 3Y17.54%
OCF growth 5Y5.79%
PEDIATRIX MEDICAL GROUP INC / MD Fundamental Analysis FAQ
What is the ChartMill fundamental rating of PEDIATRIX MEDICAL GROUP INC (MD) stock?
ChartMill assigns a fundamental rating of 6 / 10 to MD.
Can you provide the valuation status for PEDIATRIX MEDICAL GROUP INC?
ChartMill assigns a valuation rating of 8 / 10 to PEDIATRIX MEDICAL GROUP INC (MD). This can be considered as Undervalued.
Can you provide the profitability details for PEDIATRIX MEDICAL GROUP INC?
PEDIATRIX MEDICAL GROUP INC (MD) has a profitability rating of 7 / 10.
Can you provide the financial health for MD stock?
The financial health rating of PEDIATRIX MEDICAL GROUP INC (MD) is 6 / 10.